在SPOP的MATH域与其生理伙伴之间结合机制的生物物理特征
Awa Diop1, Paola Pietrangeli1, Caterina Nardella1
1Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Dipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, P.le Aldo Moro 5, 00185 Rome, Italy.
International journal of molecular sciences
|June 28, 2023
概括
斑点型POZ蛋白 (SPOP) 通过其MATH域结合基质. 这项研究详细介绍了SPOP MATH域如何识别关键蛋白质,为疾病机制提供了洞察力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 结构生物学 结构生物学
背景情况:
- 斑点类型的POZ蛋白 (SPOP) 作为E3泛基因酶适配剂,调节基质泛基因化.
- SPOP利用蛋白质-蛋白质相互作用域,包括MATH域,用于基质识别.
- MATH域对各种细胞通路至关重要,并与人类疾病有关.
研究的目的:
- 通过实验来描述SPOP MATH域的结合机制.
- 为了研究与模仿Puc,MacroH2A和PTEN的的相互作用.
- 阐明关键的MATH域残留在基质识别中的作用.
主要方法:
- 生物化学结合测试以表征SPOP MATH域相互作用.
- 位点定向的突变发生,以探测关键残留物的功能.
- 与MATH域相互作用的现有数据进行比较分析.
主要成果:
- 详细描述SPOP MATH域与三种不同的基质之间的结合机制.
- 在MATH领域内确定关键的残留物,这对于调解这些相互作用至关重要.
- 了解SPOP如何识别并与其多样化的生理伙伴结合.
结论:
- 这项研究提供了对SPOP MATH域基板识别的机制性理解.
- 这些发现有助于理解SPOP在细胞通路和疾病中的作用.
- 这项工作为进一步对SPOP介导无处不在的结构和功能研究奠定了基础.
相关概念视频
Physiological Pharmacokinetic Models: Assumption with Protein Binding
76
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
76
The Equilibrium Binding Constant and Binding Strength
13.0K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.0K
Protein-Drug Binding: Mechanism and Kinetics
647
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
647
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Ligand Binding Sites
12.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.9K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
145
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
145


